The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Smirnova O.M.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Ivannikova E.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Therapy of diabetes mellitus and the risk of malignization

Authors:

Smirnova O.M., Ivannikova E.V.

More about the authors

Journal: Problems of Endocrinology. 2012;58(2): 52‑57

Views: 1284

Downloaded: 17

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Smirnova OM, Ivannikova EV. Therapy of diabetes mellitus and the risk of malignization. Problems of Endocrinology. 2012;58(2):52‑57. (In Russ.)

МСФ на ЯМ
Close metadata
Recommended articles:
Endo­thelial dysfunction as a pathogenetic factor of sensorineural hearing loss. Russian Bulletin of Otorhinolaryngology. 2024;(1):21-27
Causes of hospital mortality in adults based on medi­cal certificates of death. Russian Journal of Preventive Medi­cine. 2024;(3):7-13
Opti­mizing the treatment of diabetic ketoacidosis. Russian Journal of Anesthesiology and Reanimatology. 2024;(2):67-77
Modern issues of lung tube­rculosis and diabetes mellitus on the toba­cco consumption background in the world and the Russian Fede­ration. Russian Journal of Preventive Medi­cine. 2024;(4):97-102
Outcomes of bima­nual vitreoretinal surgery in the treatment of diabetic reti­nopathy complications. Russian Annals of Ophthalmology. 2024;(2-2):21-27
Impact of SGLT2 inhi­bitors on erythropoiesis and iron exchange in patients with diabetes mellitus and chro­nic heart failure. Russian Journal of Preventive Medi­cine. 2024;(5):103-110
Inci­dence of carbohydrate meta­bolism diso­rder in iron overload of different etiology. Russian Journal of Preventive Medi­cine. 2024;(5):111-117
Fatal case of rhinocerebral muco­rmycosis on the background of type II diabetes mellitus. Russian Journal of Archive of Pathology. 2024;(3):52-58
Enda­rterectomy from supe­rficial femo­ral artery in patients with type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):285-293
Evaluation of reva­scularization effi­ciency using near-infrared oximetry in patients with diabetic foot syndrome. Piro­gov Russian Journal of Surgery. 2024;(6):20-27

The safety of therapy of diabetes mellitus with hyperglycemic agents is a challenging problem in modern diabetology extensively discussed in the last years, with the special emphasis being laid on the associated risk of formation and development of various neoplasms. The main forms of cancer known to occur in association with type 2 diabetes mellitus are related to obesity and insulin resistance. It suggests the important role of various factors, besides hyperinsulinism and hyperglycemia, in cancer pathogenesis. The present review is designed to analyse the influence of insulin analogs, sulphonylurea derivatives, metformin, and thiazolidindiones on the risk of malignization in the patients with diabetes mellitus.

Keywords:

diabetes mellitus
risk of cancer
sulphonylurea
insulin analogs
metformin
thiazolidindiones

Authors:

Smirnova O.M.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Ivannikova E.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

List of references:

  1. Coughlin S.S. Diabetes mellitus as a predictor cancer mortality in a large cohort of US adults. Am J Epidem 2004; 159: 1160-1167.
  2. Larsson S.C., Orsini N., Wolk A. Diabetes millitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 679-1687.
  3. Huxley R., Ansary-Moghaddam I.A., Berrington de Gonzalez A., Barzi F., Woodward M. Type 2 diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 2005; 92: 2076-2083
  4. Larsson S.C., Mantzoros C.S., Wolk A. Diabetes Mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121: 856-862.
  5. Smith U., Gale E.A. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 2 (9): 1699-708.
  6. Giovannucci E., Michand D. A role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterol 2007; 132: 2208-2225.
  7. Evans J.M.M., Donnelly L.A., Emslie-Smith A.M., Allessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetes patients. BMJ 2005; 330: 1304-1305.
  8. Currie C.J., Pool C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52 (9): 1766-1777.
  9. Motoshima H., Goldstein B.J., Igata M., Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006; 574 (Pt 1): 63-71.
  10. Dankner R., Chetrit A., Segal P. Glucose tolerance status and 20 year cancer incidence. Israel Med Assoc J 2007; 9: 592-596.
  11. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N E J Med 2003; 348: 1625-1638.
  12. Key T.J., Appleby P.N., Reeves G.K., Roddam A., Dorgan J.F., Longcope C., Stanczyk F.Z., Stephenson H.E. Jr., Falk R.T., Miller R. et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Nat Cancer Institute 2003; 95: 1218-1226.
  13. Cleary M.P., Ray A., Rogozina O.P., Dogan S., Grossmann M.E. Targeting the adiponectin: leptin ratio for postmenopausal breast cancer prevention. Frontiers in Bioscience 2009; 1: 329-357.
  14. Bershtein L.M. Gipolipidemicheskie i antidiabeticheskie preparaty kak sredstvo preduprezhdeniya i terapii zlokachestvennykh opukholei: klinicheskie dannye NII onkologii im. prof. N.N. Petrova MZ RF, Sankt-Peterburg. Rossiiskii onkologicheskii kongress, 8-i: Sbornik tezisov. M 2004.
  15. Dedov I.I., Balabolkin M.I. Insulinovaya rezistentnost' i rol' gormonov zhirovoi tkani v razvitii sakharnogo diabeta. M 2005.
  16. Postic C., Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes and Metabolism 2008; 34: 643-648.
  17. Vigneri P., Frasca F. Sciacca L., Pandini G., Vigneri R. Diabetes and cancer. Endocr Rel Cancer 2009; 16: 4: 1103-1123.
  18. Caldwell S., Lazo M. Is exercise an effective treatment for NASH? Knowns and unknowns. Ann Hepatol 2009; 8: Suppl 1: S60-S66.
  19. Ceriello A., PaolissoG. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 3: 257-267.
  20. Bowker S.L., Veugelers P., Majumdar S.R., Jonson J.A. Increased Cancer-Related Mortalitt for Patients With Type 2 Diabetes Who Use Sulfanilureas or Insulin. Diabetes Care 2006; 29: 254-258.
  21. Session D.R., Kalli K.R., Tummon I.S. et al. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol 2003; 17: 405-407.
  22. Hardie D.G. The AMP-activated protein kinase pathway - new players upstream and downstream. J. Cell Sci 2004; 117: 5479-5487.
  23. Zalevskaya A.G., Patrakeeva E.M. Metabolicheskaya regulyatsiya i tsAMF-zavisimaya proteinkinaza (AMPK): vrag ili soyuznik? Sakharnyi diabet 2008; 4: 12-18.
  24. Holly J.M., Perks C.M. Cancer as an endocrine problem. Best Pract Res Clin Endocrinol Metab 2008; 22: 4: 539-550.
  25. Ondrey F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 2009; 8: 15: 2.
  26. Lewis S. Nested case control studies. Gastroenterology 2006; 46: 432-437.
  27. Home P.D. Lancet. Diabetology 2009; 373: 2125-2135.
  28. Gullo L., Pezzlini R., Morselli-Labate A.M. Diabetes and risk of pancreatic cancer. N Eng Med 1994: 331-381.
  29. Chow W.-H., Gredley G., Nyren O. et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995; 87: 930.
  30. Everhart J., Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273: 165.
  31. Harmel A.P., Mathur R., Davidson M.B. Davidson's diabetes mellitus: diagnosis and treatment. 5th ed. Philadelphia 2004.
  32. Hemkens L.G., Grouven U., Bender R., Gunster C., Gutschmidt S., Selke G.W., Sawicki P.T. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 9: 1732-1744.
  33. Colhoun H.M., SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network. Diabetologia 2009; 52: 9: 1755-1765.
  34. The ORIGIN Trial (Outcome ReductionWith Initial Glargine Intervention) [registered clinical trial], 2009. Clinical trialreg. no. NCT00069784, clinical trials gov. Accessed 5 April 2010.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.